GPN Vaccines is a vaccine that is used to prevent the spread of streptococcus pneumoniae.
GPN Vaccines has raised $12.0M in total funding. The most recent round was Series B. The last funding was announced in June 2024.
GPN Vaccines's investors include Forepont Capital Partners, Shearwater Capital, National Health and Medical Research Council, Kern Whelan Capital, Government of South Australia.
GPN Vaccines is headquartered in Adelaide, Australia.
GPN Vaccines is a vaccine that is used to prevent the spread of streptococcus pneumoniae.
GPN Vaccines is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"GPN Vaccines — Funding & Investors." VCBacked, June 6, 2024, https://www.vcbacked.co/company/gpn-vaccines. Accessed September 30, 2026.
VCBacked. (2024). GPN Vaccines — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/gpn-vaccines
{{cite web |title=GPN Vaccines — Funding & Investors |url=https://www.vcbacked.co/company/gpn-vaccines |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated